via itech.dickinson.edu
A single dose of psilocybin, the major hallucinogenic component in magic mushrooms, induces long-lasting decreases in anxiety and depression in patients diagnosed with life-threatening cancer according to a new study presented today at the annual meeting of the American College of Neuropsychopharmacology.
Patients who receive a cancer diagnosis often develop debilitating symptoms of anxiety and depression. Reports from the 1960s and 1970s suggest that hallucinogenic drugs such as LSD may alleviate such symptoms in cancer patients, but the clinical value of hallucinogenic drugs for the treatment of mood disturbances in cancer patients remains unclear. In this new study, Roland Griffiths and colleagues from the Johns Hopkins University School of Medicine investigated the effects of psilocybin on symptoms of anxiety and depression in individuals diagnosed with life-threatening cancer. Five weeks after receiving a dose of psilocybin sufficiently high to induce changes in perception and mystical-type experiences, patients reported significantly lower levels of anxiety and depression compared with patients that received a low dose of the drug. The positive effects on mood persisted in the patients at 6 month follow-up.
The authors suggest that a single dose of psilocybin may be sufficient to produce enduring decreases in negative mood in patients with a life-threatening cancer.
Read more: Active ingredient in magic mushrooms reduces anxiety and depression in cancer patients
The Latest on: Psilocybin
via Google News
The Latest on: Psilocybin
- Psychedelic drug research center started at UW-Madisonon August 23, 2021 at 9:25 am
The move expands research on psilocybin, MDMA and other compounds to treat depression and other mental health disorders.
- Novel Derivative of Psilocybin May Provide a More Accessible, Effective Form of Treatment for PTSDon August 23, 2021 at 7:01 am
Col. Dallas Hack, director of medical affairs at MagicMed, discusses the drug development program of a novel derivative of psilocybin for the treatment of post-traumatic stress disorder.
- Psyched: Beckley Psytech Raises $80M, Diamond Therapeutics To Study Psilocybin Microdosing, Mydecine and Johns Hopkins Partner Upon August 23, 2021 at 6:01 am
Beckley Psytech Closes $80 Million Series B Beckley Psytech announced the closing of a £58 million ($80 million) Series B raise, which will be used to further finance the company’s psilocybin and ...
- Most mental health patients support further research into the therapeutic potential of psilocybin, study findson August 18, 2021 at 4:43 pm
People who use mental health services in Ireland generally have a favorable view of psychedelic research, according to a new study published in the Irish ...
- This Canadian Company Is Launching A Psilocybin Microdosing Studyon August 18, 2021 at 4:34 pm
Diamond Therapeutics Inc., a biotech company in the psychedelics sector has received authorization from Health Canada to launch a clinical trial to study the effects of low doses of psilocybin in ...
- California Bill To Legalize Possession Of Psychedelics Clears Another Hurdle But Faces Key Challenge Next Weekon August 18, 2021 at 2:48 pm
A Senate-passed bill to legalize possession of certain psychedelics in California cleared a procedural hurdle on Monday—but it faces another critical challenge in the Assembly next week that could ...
- Tryp Therapeutics Appoints Dennis Langer, M.D., J.D. as Senior Advisoron August 18, 2021 at 4:08 am
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today ...
- Diamond Therapeutics Announces Health Canada Approval of Clinical Trial with Low-Dose Psilocybinon August 17, 2021 at 5:23 am
PRNewswire/ - Diamond Therapeutics Inc. ('Diamond'), a drug development company focused on low-dose psychedelic therapies ...
- Revive Therapeutics advancing psilocybin to FDA clinical studies for methamphetamine use disorder and strokeon August 10, 2021 at 6:03 am
The company is working with the University of Wisconsin System to conduct a Phase I/II clinical study to evaluate the safety and feasibility ...
- IHL’s global research team lays out the blueprint for its psilocybin therapy development pathway, shares climbon August 10, 2021 at 1:26 am
The company’s latest update clearly illustrates the rigorous testing approach adopted by IHL’s world-leading research team at Monash University.
via Bing News
